METTL3 and leukemia: These inhibitors, such as Eltrombopag and CDIBA-4, bind directly the METTL3–METTL14 heterodimer, impacting its catalytic activity, which correlates with severely impaired proliferation in MOLM-13 cells and other leukemia cell lines (137,138).